Idenix Pharmaceuticals (IDIX)

[DewDiligence]

Re: MS webcast

JP predicts a 30% SVR rate in geno-1 partial responders on original SoC (>=2-log reduction without PCR-negativity) who are retreated with NM283+PI+peg-ifn+riba.

This is of course a tall order. There is no approved treatment for this patient population, and there is no off-label regimen that gives anything close to a 30% SVR rate.